J Macías1,2, L M Real3,4, A Rivero-Juárez5, N Merchante3,4, A Camacho5, K Neukam3,4, A Rivero5, M Mancebo3,4, J A Pineda3. 1. Infectious Diseases and Microbiology Unit, Valme University Hospital, Seville, Spain. juan.macias.sanchez@gmail.com. 2. Institute of Biomedicine from Seville (IBiS), Seville, Spain. juan.macias.sanchez@gmail.com. 3. Infectious Diseases and Microbiology Unit, Valme University Hospital, Seville, Spain. 4. Institute of Biomedicine from Seville (IBiS), Seville, Spain. 5. Infectious Diseases Unit, Institute Maimónides of Biomedical Research from Cordoba, Cordoba, Spain.
Abstract
OBJECTIVES: There are scant data on the progression of hepatic steatosis (HS) in HIV infection. We therefore evaluated changes in HS over time in HIV-infected patients using the controlled attenuation parameter (CAP). METHODS: A prospective cohort of 326 HIV-infected patients was included in this study. All patients underwent a CAP measurement. Changes in steatosis were evaluated by calculating the median (Q1-Q3) difference between baseline and 12-month CAP values. RESULTS: The median (Q1-Q3) CAP was 221 (196-252) dB/m at baseline and 224 (198-257) dB/m at the 12-month visit (P = 0.617). Significant steatosis, that is, CAP ≥ 238 dB/m, was observed in 76 individuals (37%) at baseline and in 80 (39%) at the 12-month visit (P = 0.683). The following variables were associated with ΔCAP: plasma HIV RNA [< 50 vs. ≥ 50 HIV-1 RNA copies/mL: median (Q1-Q3) ΔCAP, 4 (-21, 27) vs. -21 (-49, 4) dB/m, respectively; P = 0.024]; body mass index (BMI) [no increase vs. increase: -13 (-40, 4) vs. 14 (-6, 32) dB/m, respectively; P < 0.001]; triglycerides [no increase vs. increase: -1 (-30, 22) vs. 15 (-3, 40) dB/m, respectively; P = 0.001]; fasting plasma glucose [not impaired vs. impaired: -4 (-31, 16) vs. 30 (15, 49) dB/m, respectively; P < 0.001]; and raltegravir [no vs. yes: 5 (-20, 29) vs. -11 (-37.5, 15) dB/m, respectively; P = 0.018]. The only factor independently associated with ΔCAP was BMI [B (standard error): 9.03 (1.9); P < 0.001]. CONCLUSIONS: Increases in CAP values over a period of 12 months in HIV-infected patients were strongly associated with elevations in BMI. Other metabolic factors and antiretroviral drugs were not predictors of CAP changes independent of BMI.
OBJECTIVES: There are scant data on the progression of hepatic steatosis (HS) in HIV infection. We therefore evaluated changes in HS over time in HIV-infectedpatients using the controlled attenuation parameter (CAP). METHODS: A prospective cohort of 326 HIV-infectedpatients was included in this study. All patients underwent a CAP measurement. Changes in steatosis were evaluated by calculating the median (Q1-Q3) difference between baseline and 12-month CAP values. RESULTS: The median (Q1-Q3) CAP was 221 (196-252) dB/m at baseline and 224 (198-257) dB/m at the 12-month visit (P = 0.617). Significant steatosis, that is, CAP ≥ 238 dB/m, was observed in 76 individuals (37%) at baseline and in 80 (39%) at the 12-month visit (P = 0.683). The following variables were associated with ΔCAP: plasma HIV RNA [< 50 vs. ≥ 50 HIV-1 RNA copies/mL: median (Q1-Q3) ΔCAP, 4 (-21, 27) vs. -21 (-49, 4) dB/m, respectively; P = 0.024]; body mass index (BMI) [no increase vs. increase: -13 (-40, 4) vs. 14 (-6, 32) dB/m, respectively; P < 0.001]; triglycerides [no increase vs. increase: -1 (-30, 22) vs. 15 (-3, 40) dB/m, respectively; P = 0.001]; fasting plasma glucose [not impaired vs. impaired: -4 (-31, 16) vs. 30 (15, 49) dB/m, respectively; P < 0.001]; and raltegravir [no vs. yes: 5 (-20, 29) vs. -11 (-37.5, 15) dB/m, respectively; P = 0.018]. The only factor independently associated with ΔCAP was BMI [B (standard error): 9.03 (1.9); P < 0.001]. CONCLUSIONS: Increases in CAP values over a period of 12 months in HIV-infectedpatients were strongly associated with elevations in BMI. Other metabolic factors and antiretroviral drugs were not predictors of CAP changes independent of BMI.
Authors: Jennifer C Price; Jennifer L Dodge; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan Noworolski; Phyllis C Tien Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Mihály Sulyok; Tamás Ferenci; Mihály Makara; Gábor Horváth; János Szlávik; Zsófia Rupnik; Luca Kormos; Zsuzsanna Gerlei; Zita Sulyok; István Vályi-Nagy Journal: PeerJ Date: 2017-01-11 Impact factor: 2.984
Authors: Hugo Perazzo; Sandra W Cardoso; Carolyn Yanavich; Estevão P Nunes; Michelle Morata; Nathalia Gorni; Paula Simplicio da Silva; Claudia Cardoso; Cristiane Almeida; Paula Luz; Valdilea G Veloso; Beatriz Grinsztejn Journal: J Int AIDS Soc Date: 2018-11 Impact factor: 5.396